1,618 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Aigen Investment Management LP

Aigen Investment Management LP bought a new position in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,618 shares of the company’s stock, valued at approximately $1,433,000.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Prime Capital Investment Advisors LLC increased its position in shares of Eli Lilly and Company by 2.6% during the third quarter. Prime Capital Investment Advisors LLC now owns 64,372 shares of the company’s stock valued at $57,030,000 after acquiring an additional 1,635 shares during the last quarter. Total Investment Management Inc. increased its position in shares of Eli Lilly and Company by 10.1% during the 3rd quarter. Total Investment Management Inc. now owns 261 shares of the company’s stock valued at $231,000 after purchasing an additional 24 shares during the last quarter. Savvy Advisors Inc. raised its stake in shares of Eli Lilly and Company by 4.9% during the 3rd quarter. Savvy Advisors Inc. now owns 1,892 shares of the company’s stock worth $1,676,000 after purchasing an additional 88 shares during the period. Ashton Thomas Private Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 5.1% in the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 16,358 shares of the company’s stock worth $14,492,000 after buying an additional 798 shares during the last quarter. Finally, Proactive Wealth Strategies LLC bought a new position in Eli Lilly and Company during the third quarter valued at about $392,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $3.91 during trading on Tuesday, hitting $828.53. The stock had a trading volume of 303,858 shares, compared to its average volume of 3,101,369. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm has a market cap of $786.54 billion, a price-to-earnings ratio of 90.09, a P/E/G ratio of 3.15 and a beta of 0.43. The business’s 50-day moving average is $893.78 and its 200 day moving average is $870.11.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter last year, the business posted $0.10 EPS. The business’s quarterly revenue was up 20.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.63%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Wall Street Analyst Weigh In

Several analysts have commented on LLY shares. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective on the stock. Barclays dropped their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Bank of America dropped their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.